Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients

Overview of attention for article published in Journal of Translational Medicine, August 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (71st percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

So far, Altmetric has seen 8 X posts from 6 X users, with an upper bound of 11,221 followers.

In honor of #BladderCancerMonth23, today we are highlighting our DetermaIO publications in advanced urothelial carcinoma: 1. Nielsen, et al. https://t.co/atmQThtUT0 2. Seitz, et al. https://t.co/wEJq6ll5iz #DetermaIO #Bladdercancer #OCX $OCX https://t.co

RT @OCX_IR: DetermaIO™ outperformed nineteen other genomic signatures and additional existing biomarkers originally selected for testing. […

DetermaIO™ outperformed nineteen other genomic signatures and additional existing biomarkers originally selected for testing. [Journal of Translational Medicine August 16, 2022] https://t.co/7fjwjX1QG3 #bladdercancer #oncology #biomarkers $OCX https://t.co

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 4 additional X posts.